Overview
|
L-701,324 (#L-195) is a highly pure, synthetic and biologically active compound.
Applications
- Alomone Labs L-701,324 inhibits NMDA (NR1+NR2A) receptors expressed in Xenopus oocytes.A. Representative time course of NR1/NR2A currents, elicited by transient stimulations with 2
µM glutamate + 10 µM glycine every 50 sec, while membrane potential was held at -80 mV, and significantly inhibited by 5 nM L-701,324 (#L-195).
B. Superimposed current traces from the recording shown in A, following application of control and 5 nM L-701,324. Transient stimulation is indicated by an arrow.
Specifications
Technical Specifications
Biological Activity
- Priestley, T. et al. (1996) Neuropharmacol. 35, 1573.
- Traynelis S. F. et al. (2010) Pharmacol. Rev., 62, 405,
Solubility and Storage
Soluble in DMSO. It is recommended to prepare fresh solutions before use. Centrifuge all products before use (10000 x, g 5 min). Avoid multiple freezing and thawing.
Scientific Background
Glutamate is a central excitatory neurotransmitter in the nervous system and his mediating signaling is important for basic neuron-to-neuron signaling and neuronal processes such as learning, memory and pain perception. N-methyl-D-aspartate (NMDA) receptor are the major subtype of glutamate receptors that participate in synaptic transmission. NMDA receptor consists of three different subunits termed GluN1-3. Activation of NMDA receptor carried out via interaction with glycine and glutamate1.
L-701,324 (7-chloro-4-hydroxy-3(3-phenoxy) phenylquinoline-2-(H)-on) is an effective NMDA antagonist that antagonizes the activity of the NMDA receptor by blocking its glycine binding site. It was found that L-701,324 when administered orally has an inhibitory effect on spreading depression (SD) initiations and propagation2. Moreover L-701,324 act as anticonvulsant and neuroprotective agent3. Recently it was shown that antidepressant effect of L-701,324 in mice IS mediated by elevating the hippocampal BDNF signaling cascade4.
- Vyklicky, V. et al. (2014) Physiol. Res., 63, S191.
- Obrenovitch, T. P. et al. (1996) Br. J. Pharmacol., 117, 931.
- Obrenovitch, T.P. et al. (1997) Naunyn-Schmiedeberg's Arch Pharmacol., 355, 779.
- Liu, L. et al. (2021) Behav. Brain Res., 399, 113038.